BNT113
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BNT113, covering 2026-04-15 to 2026-04-15. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 [Phase 2, Phase 3]